Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Conclusions
These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed. A future randomized study of genotype-guided antiplatelet therapy may be of value.

Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 15, 2018 Category: Cardiology Authors: Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., Pratt, V. M., Alestock, T. D., Anderson, R. D., Alsip, J., Ardati, A. K., Brott, B. C., Brown, L., Ch Tags: Coronary Source Type: research